The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
about
Hydroxychloroquine-related retinal toxicityChloroquine treatment enhances regulatory T cells and reduces the severity of experimental autoimmune encephalomyelitisSpectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision lossThe impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women.Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy.European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studiesSpectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the "flying saucer" sign)Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.Extrapulmonary manifestations of sarcoidosis.Retinal toxicity associated with chronic exposure to hydroxychloroquine and its ocular screening. Review.Early retinal and retinal nerve fiber layer effects of hydroxychloroquine: a follow up study by sdOCT.Common synonymous variants in ABCA4 are protective for chloroquine induced maculopathy (toxic maculopathy).High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy.Multifocal ERG Guiding Therapy in a Case of Hydroxychloroquine Premaculopathy.Hydroxychloroquine retinopathy: A review of imagingA case of severe hydroxychloroquine-induced retinal toxicity in a patient with recent onset of renal impairment: a review of the literature on the use of hydroxychloroquine in renal impairment.Detection of Hydroxychloroquine Retinal Toxicity by Automated Perimetry in 60 Rheumatoid Arthritis Patients with Normal Fundoscopic Findings.Optical coherence tomography based microangiography findings in hydroxychloroquine toxicityKilling of Escherichia coli by Crohn's Disease Monocyte-derived Macrophages and Its Enhancement by Hydroxychloroquine and Vitamin DSelective thinning of the perifoveal inner retina as an early sign of hydroxychloroquine retinal toxicity.Microperimetric sensitivity in patients on hydroxychloroquine (Plaquenil) therapy.Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases.The 'non-falciparum' malarias: the roles of epidemiology, parasite biology, clinical syndromes, complications and diagnostic rigour in guiding therapeutic strategies.Hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis and its safety in pregnancy.The role of antimalarial agents in the treatment of SLE and lupus nephritis.Hydroxychloroquine retinopathy combined with retinal pigment epithelium detachment.Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists.Ocular manifestations in systemic lupus erythematosus.Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety.Research progress of hydroxychloroquine and autophagy inhibitors on cancer.Hydroxychloroquine retinopathy.Hydroxychloroquine retinopathy: an emerging problem.Factors associated with chloroquine-induced retinopathy in rheumatic diseases.Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness.Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy.Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.Retinal functional changes measured by frequency-doubling technology in patients treated with hydroxychloroquine.Causes of DMARD withdrawal following ADR within 6 months of initiation among Indian rheumatoid arthritis patients.
P2860
Q26782822-F4948B9A-C957-46BF-9EDD-C7616F35CC01Q28533957-576F2757-FAF2-4B73-8A77-5D2730776AFAQ33623421-457AC60A-85D1-45CE-BA5A-3F2C8424617EQ33976159-1E4DBF34-E541-40DA-A385-6F73FAA19BB0Q34005507-E44023E6-0236-46B9-A9D6-923372904E6AQ34187282-352FA80E-A217-485A-A6A9-5A80BDDA26C9Q34245232-852AF23E-F628-443E-B3FE-DA38546FBD28Q34315879-0B67F091-E3AC-4C3D-BD1B-82C6CAA5FED8Q34340121-AE851972-DB31-4D3C-B955-AB9FED7E7F0DQ34520106-E20296EE-24AB-4144-BD28-2D36BF46C8C1Q34563915-A1D7989D-FA83-4B3D-9B8A-7CF8AA1948F9Q35155368-34027DD0-EA2F-4AED-862D-E115D8E8578CQ36012432-37A29279-7BF9-468D-A3F4-D0117B34EB02Q36236306-C35B1E52-429C-40C7-B3BB-7AEE8382E51BQ36298100-2F2B3DAE-6037-46AD-A72E-830E6306B215Q36470464-09886F52-D2B6-4EB4-BB88-2A9B550CF70BQ36718495-D25B49B9-073E-45D7-BFAB-D0CC25896B1BQ36874474-4EAD979F-1E15-41B9-864A-F39E91EEF916Q36973431-15840F8C-598A-4E22-B12C-28D451E1A891Q37012243-6D89F6E1-0182-4CCA-B399-8D75C9C03B20Q37168797-52719069-DF62-4295-8BEA-7FC1C21E5D6FQ37622345-8C83056B-B769-453E-B927-712D3FBEFBC5Q37775719-EB773D97-FD2D-47BE-82D8-808C64A8452AQ37854742-814D6C81-CEFA-4C8B-B6FD-C9783A0E74A9Q37947108-29129D2D-D96B-4B97-83F7-0BA490B30231Q37952267-3BE84F3C-53CC-4E0E-960A-05473CFFB4F3Q38029146-0FFADC0A-0DFD-448F-896A-C929678F519EQ38411930-F5DDC4F3-F071-4F1A-BE35-1C866AFB5EB1Q38436812-C9986FA6-BFC8-49D2-8DCE-15AFCF33E6FEQ38658480-91A143D2-8FFC-4572-B941-32BA19C95E6EQ39021076-3249FCC7-70E5-4689-9F27-A24CC5B0C9DBQ39172826-A40FC82E-C2ED-4D20-AEDA-6704E5AC2935Q41913394-DCF705B0-27D9-430F-9323-4E3C1C59712CQ41914430-43B0ADF0-5AD2-4557-AF11-709325438B48Q41920639-135BC82B-EA3A-43F4-8E55-812B9163C289Q41926617-8DA16BDB-7F7C-4510-A4A3-A004D75E5101Q41926681-DE9D0384-4614-4A2F-8B3E-DE2B631B2BB5Q41930905-9AB92DC0-599C-45F4-B4CB-D3EA818511B1Q41933843-03829A48-66E3-447A-B5AB-725108BA953AQ41934162-52350BDA-C8D8-4767-AC70-49F052AB5651
P2860
The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
The incidence of irreversible ...... oxychloroquine: a reappraisal.
@en
type
label
The incidence of irreversible ...... oxychloroquine: a reappraisal.
@en
prefLabel
The incidence of irreversible ...... oxychloroquine: a reappraisal.
@en
P2093
P1433
P1476
The incidence of irreversible ...... oxychloroquine: a reappraisal.
@en
P2093
Athanasios Nikolaou
Charalambos Kostopoulos
Emmanouil Mavrikakis
Ioannis Mavrikakis
Kostantinos Rougas
Myron Mavrikakis
Petros P Sfikakis
P304
P356
10.1016/S0161-6420(03)00409-3
P577
2003-07-01T00:00:00Z